Michael Hochman

Assistant Professor

Winship Cancer Institute

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Michael Hochman is an Assistant Professor at the Winship Cancer Institute in the United States. His research areas focus on myeloid neoplasms, myelodysplastic syndromes, and the impact of genetic factors on hematological disorders. Recent articles authored by Professor Hochman explore the management of clonal plasma cell disorders, prognostic implications in acute myeloid leukemia, and the relationship between different hematopoietic malignancies.

Articles (11)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (4)

Paul Hendrie

University of Washington

UNITED STATES

View details

David Allan

National Heart Lung and Blood Institute

UNITED STATES

View details

Megan Othus

Fred Hutchinson Cancer Research Center

UNITED STATES

View details

Alexander J. Ambinder

Johns Hopkins University School of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michael Hochman

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Dissecting Out a Rare Mutation, STAT: Features of STAT3-Mutant Myeloid Neoplasms

SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis

SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes

Management of patients with concurrent clonal plasma cell and myeloid disorders: A single center descriptive case series

Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification

On the basis of sex: outcomes in myelodysplastic syndromes.

Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency.

Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML)

Systematic improvements in lentiviral transduction of primary human natural killer cells undergoing <i>ex vivo</i> expansion.

Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms

Coincidence of autoimmune hemolytic anemia and pure red cell aplasia in a patient with CLL

Collaborators (4)

Paul Hendrie

David Allan

Megan Othus

Alexander J. Ambinder

Make your next move.